



THE COMMITTEE OF EUROPEAN SECURITIES REGULATORS

**Certificate of Approval of a Prospectus
pursuant to The Prospectus Regulations 2005**

To:
COMMISSION BANCAIRE, FINANCIERE ET DES ASSURANCES (BELGIUM)

From:
The Financial Conduct Authority
25 The North Colonnade, Canary Wharf, London E14 5HS, United Kingdom

We hereby certify that the Single Prospectus detailed below has been drawn up in accordance with Directive 2003/71/EC as amended by the Directive 2010/73/EU or national law transposing the Directive and was approved by the FCA on 2nd March 2018.

Name of Issuer: Acacia Pharma Group Limited

Registered Office/Seat: England and Wales

Type of Securities: Global Offer of 11,111,111 Ordinary Shares of £0.02 each and admission of all Ordinary Shares to trading on the regulated market of Euronext Brussels

Guarantor (if any): N/A

Annexes: 1,2,3 and 22

National Prospectus Identifier: PRO04140

We have authorised, in accordance with Article 8 of Directive 2003/71/EC as amended by the Directive 2010/73/EU or national law transposing Directive 2003/71/EC as amended, the omission of the information on the following grounds: **No omission**

Attachments:

1. Single Prospectus dated 2nd March 2018.

Financial Conduct Authority
Document Approved
Date: 2/3/18
Signed: 